Data / Drug companies / Cisatracurium besylate
Cisatracurium besylate: 15 companies and 41 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Cisatracurium besylate is listed in the FDA National Drug Code Directory by 15 companies, with 41 products in commercial distribution. 41 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection; injection, solution, and the newest product started marketing on August 15, 2026.
The request: Get every company that lists cisatracurium besylate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 15
- Products
- 41
- Generic (ANDA) products
- 41 (100.0%)
- Application numbers
- 20
- Routes
- Intravenous
- Brand names
- Cisatracurium
- openFDA record search
- api.fda.gov
Companies that list cisatracurium besylate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Meitheal Pharmaceuticals Inc. | 6 | injection, solution | Generic drugs (ANDA) | October 31, 2019 |
| Camber Pharmaceuticals, Inc. | 3 | injection | Generic drugs (ANDA) | May 4, 2026 |
| Caplin Steriles Limited | 3 | injection | Generic drugs (ANDA) | January 17, 2025 |
| Fresenius Kabi USA, LLC | 3 | injection, solution | Generic drugs (ANDA) | February 26, 2015 |
| Gland Pharma Limited | 3 | injection | Generic drugs (ANDA) | March 19, 2025 |
| Hikma Pharmaceuticals USA Inc. | 3 | injection | Generic drugs (ANDA) | March 17, 2025 |
| Hospira, Inc. | 3 | injection, solution | Generic drugs (ANDA) | March 24, 2020 |
| Sandoz Inc | 3 | injection | Generic drugs (ANDA) | July 16, 2012 |
| Slate Run Pharmaceuticals, LLC | 3 | injection | Generic drugs (ANDA) | December 1, 2023 |
| Somerset Therapeutics, LLC | 3 | injection | Generic drugs (ANDA) | August 2, 2019 |
| Eugia US LLC | 2 | injection | Generic drugs (ANDA) | October 27, 2020 |
| Zydus Lifesciences Limited | 2 | injection | Generic drugs (ANDA) | February 12, 2020 |
| Zydus Pharmaceuticals USA Inc. | 2 | injection | Generic drugs (ANDA) | February 12, 2020 |
| Armas Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | January 15, 2025 |
| Avenacy, LLC | 1 | injection, solution | Generic drugs (ANDA) | August 15, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 28 | 68.3% |
| Injection, solution | 13 | 31.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 41 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Nondepolarizing Neuromuscular Blocker | 41 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.